BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grebely J, Dore GJ, Alami NN, Conway B, Dillon JF, Gschwantler M, Felizarta F, Hézode C, Tomasiewicz K, Fredrick LM, Dumas EO, Mensa FJ. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy 2019;66:73-9. [PMID: 30735896 DOI: 10.1016/j.drugpo.2019.01.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association 2020;119:1135-57. [DOI: 10.1016/j.jfma.2020.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
2 González-Serna A, Macias J, Corma-Gomez A, Tellez F, Cucurull J, Real LM, Granados R, Rivero-Juarez A, Hernandez-Quero J, Merino D, Palacios R, Ríos MJ, Collado A, Pineda JA. High efficacy of Glecaprevir/Pibrentasvir for HCV-Infected individuals with active drug use. J Infect 2022:S0163-4453(22)00358-9. [PMID: 35700867 DOI: 10.1016/j.jinf.2022.06.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Klinker H, Naumann U, Rössle M, Berg T, Bondin M, Lohmann K, Koenig B, Zeuzem S, Cornberg M. Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. Liver Int 2021;41:1518-22. [PMID: 33966349 DOI: 10.1111/liv.14937] [Reference Citation Analysis]
4 Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ, Marra F. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. J Viral Hepat 2019;26:951-60. [PMID: 30977945 DOI: 10.1111/jvh.13110] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Hollande C, Parlati L, Pol S. Micro-elimination of hepatitis C virus. Liver Int. 2020;40 Suppl 1:67-71. [PMID: 32077601 DOI: 10.1111/liv.14363] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
6 Ing Lorenzini K, Girardin F. Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients. Liver Int 2019;40:32-44. [DOI: 10.1111/liv.14283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
7 Zhang W, Li S, Liu H, Zhang Y, Xie H, Peng D, Peng H, Ou Z, Peng Z, Dong W, An D. Development of the Enabling Route for a Novel HCV NS3/4A Inhibitor, Furaprevir. Org Process Res Dev . [DOI: 10.1021/acs.oprd.1c00315] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Godin A, Kronfli N, Cox J, Alary M, Maheu-Giroux M. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada. Int J Drug Policy 2021;88:102738. [PMID: 32278651 DOI: 10.1016/j.drugpo.2020.102738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
9 Hintz A, Umland T, Niess G, Guendogdu M, Moerner A, Tacke F. Pharmacotherapy Profiles in People with Opioid Use Disorders: Considerations for Relevant Drug-Drug Interactions with Antiviral Treatments for Hepatitis C. Pathogens 2021;10:648. [PMID: 34073674 DOI: 10.3390/pathogens10060648] [Reference Citation Analysis]
10 Fontana RJ, Lens S, McPherson S, Elkhashab M, Ankoma-Sey V, Bondin M, Dos Santos AGP, Xue Z, Trinh R, Porcalla A, Zeuzem S. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study. Adv Ther 2019;36:3458-70. [PMID: 31646465 DOI: 10.1007/s12325-019-01123-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Totsuka M, Honda M, Kanda T, Ishii T, Matsumoto N, Yamana Y, Kaneko T, Mizutani T, Takahashi H, Kumagawa M, Sasaki R, Masuzaki R, Kanezawa S, Nirei K, Yamagami H, Matsuoka S, Ohnishi H, Okamoto H, Moriyama M. Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir. Intern Med 2021;60:2061-6. [PMID: 33518580 DOI: 10.2169/internalmedicine.6728-20] [Reference Citation Analysis]
12 Schmidbauer C, Schubert R, Schütz A, Schwanke C, Luhn J, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. PLoS One 2020;15:e0229239. [PMID: 32155165 DOI: 10.1371/journal.pone.0229239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Lampertico P, Carrión JA, Curry M, Turnes J, Cornberg M, Negro F, Brown A, Persico M, Wick N, Porcalla A, Pangerl A, Crown E, Larsen L, Yu Y, Wedemeyer H. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. J Hepatol 2020;72:1112-21. [PMID: 32061651 DOI: 10.1016/j.jhep.2020.01.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
14 Pericot-Valverde I, Heo M, Niu J, Norton BL, Akiyama MJ, Agyemang L, Litwin AH. Declines in Depressive Symptoms Among People who Inject Drugs Treated With Direct-Acting Antivirals While on Opioid Agonist Therapy. Open Forum Infect Dis 2020;7:ofaa380. [PMID: 33381611 DOI: 10.1093/ofid/ofaa380] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
16 Messina V, Russo A, Parente E, Russo G, Raimondo T, Salzillo A, Simeone F, Onorato L, Di Caprio G, Pisaturo M, Coppola N. Innovative procedures for micro-elimination of HCV infection in persons who use drugs. J Viral Hepat 2020;27:1437-43. [PMID: 32810330 DOI: 10.1111/jvh.13375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Liu X, Hu P. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. J Clin Transl Hepatol 2021;9:125-32. [PMID: 33604263 DOI: 10.14218/JCTH.2020.00078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ramers CB, Trooskin SB. Hepatitis C Virus in the Modern Direct-Acting Antiviral Era: Where Have All the Special Populations Gone? Clin Liver Dis (Hoboken) 2018;12:143-9. [PMID: 30988932 DOI: 10.1002/cld.786] [Reference Citation Analysis]
19 Gane E, de Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, Calleja JL, Xue Z, Burroughs M, Gutierrez JA. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Viral Hepat 2021;28:1635-42. [PMID: 34448313 DOI: 10.1111/jvh.13600] [Reference Citation Analysis]
20 Messina V, Onorato L, Di Caprio G, Claar E, Iovinella V, Russo A, Rosato V, Salzillo A, Nevola R, Simeone F, Curcio F, Pisaturo M, Coppola N. Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. Life (Basel) 2020;11:17. [PMID: 33396802 DOI: 10.3390/life11010017] [Reference Citation Analysis]